<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990141</url>
  </required_header>
  <id_info>
    <org_study_id>IGX1-PRE-CS-20-11</org_study_id>
    <nct_id>NCT04990141</nct_id>
  </id_info>
  <brief_title>Molecular Screening Method for Preeclampsia (PREMOM)</brief_title>
  <acronym>PREMOM</acronym>
  <official_title>Prospective Clinical Study for the Early Detection of Preeclampsia Based on the Molecular Screening at the First Trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iPremom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iPremom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences&#xD;
      for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as&#xD;
      well as to prevent the life-threatening consequences are needed. Thus, the detection of women&#xD;
      at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the&#xD;
      maternal contribution to PE based on defective decidualization has been evidenced and new&#xD;
      technical approaches developed to detect circulating biomolecules in blood such as RNA&#xD;
      fragments. The main objective of this study is to evaluate the diagnostic precision of the&#xD;
      molecular profile from the maternal blood analysed for the early screening of early onset&#xD;
      preeclampsia (EOPE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that there is a unique molecular profile in peripheral blood specific to&#xD;
      women who develop EOPE that allow an early assess womanÂ´s risk of developing this pregnancy&#xD;
      complication.&#xD;
&#xD;
      The purposed study is a biomedical, prospective, multicentre, case-control aimed to determine&#xD;
      the predictive value and diagnostic precision of the maternal blood molecular profile for the&#xD;
      early screening of EOPE. Late-onset preeclampsia (LOPE) and other pregnancy complications&#xD;
      (such as preterm birth, intrauterine growth restriction, gestational diabetes, placenta&#xD;
      previa, placental abruption, placenta accreta, premature rupture of preterm membranes,&#xD;
      antepartum fetal death, uterine rupture and previous vasa, among others) could be analysed as&#xD;
      a secondary outcome.&#xD;
&#xD;
      Subjects will be 9585 pregnant women recruited between 9 and 14 gestational weeks.&#xD;
      Participants will provide peripheral blood sample at three different times during pregnancy&#xD;
      to be characterised at molecular level in the iPremom laboratories (Igenomix Preeclampsia&#xD;
      SLU) after their obstetric outcome was known.&#xD;
&#xD;
      Once the 50% of the total enrolment is achieved, an interim analysis will be conducted by an&#xD;
      independent external committee. Data will be registered in an electronic Case Report Form&#xD;
      (eCRF) specifically designed for this study. Monitoring activities and data verification will&#xD;
      be performed during the whole study to ensure data quality, integrity and transparency.&#xD;
&#xD;
      The total estimated duration of the study is 30 months, of which the first 18 months will&#xD;
      correspond to the recruitment period of the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic precision of EOPE at molecular level</measure>
    <time_frame>33 weeks</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive value using the clinical outcome of pregnancy as a &quot;gold standard&quot; parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic precision of LOPE and other pregnancy complications at molecular level</measure>
    <time_frame>33 weeks</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive value using the clinical outcome of pregnancy as a &quot;gold standard&quot; parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of molecular profile in maternal blood</measure>
    <time_frame>33 weeks</time_frame>
    <description>Molecular profile (DNA/RNA/proteins/metabolites) associated to gestational age, epidemiological and clinical variables</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of candidate biomarkers in the maternal blood for therapy studies.</measure>
    <time_frame>33 weeks</time_frame>
    <description>DNA/RNA/proteins/metabolites</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">9585</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Cases group</arm_group_label>
    <description>Women recruited between 9 and 14 gestational weeks diagnosed with preeclampsia or other complication at the end of pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Women recruited between 9 and 14 gestational weeks without diagnosis of preeclampsia or other complication at the end of the pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood collection in cases group</intervention_name>
    <description>Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group</description>
    <arm_group_label>Cases group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood collection in control group</intervention_name>
    <description>Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal peripheral blood samples with circulating genetic material (C-RNA/C-DNA) and other&#xD;
      biomolecules and cellular component to provide preeclampsia information and other obstetric&#xD;
      complications.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women over the age of 18 recruited between 9 and 14 gestational weeks who attend&#xD;
        the participating referral centers for their regular gynecological-obstetric follow-up, as&#xD;
        well as their childbirth care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients whose written informed consent approved by the Ethics Committee (EC) has been&#xD;
             obtained, after having been duly informed of the nature of the study and voluntarily&#xD;
             accepted to participate after being fully aware of the potential risks, benefits and&#xD;
             any discomfort involved.&#xD;
&#xD;
          -  Women over the age of 18 at the time of signing the informed consent form.&#xD;
&#xD;
          -  Pregnant women with single gestation between weeks 9 and 14 of gestation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known malignancy&#xD;
&#xD;
          -  History of organ transplant or bone marrow transplant.&#xD;
&#xD;
          -  Maternal transfusion in the last 8 weeks prior to taking the sample.&#xD;
&#xD;
          -  Early gestational loss&#xD;
&#xD;
          -  Existence of serious or uncontrolled bacterial, fungal or viral infections that, in&#xD;
             the opinion of the investigator may interfere with the patient's participation in the&#xD;
             study or the evaluation of the results of the study.&#xD;
&#xD;
          -  Other circumstances or difficulties that, in the investigator's opinion, may suppose a&#xD;
             risk to the subject or reduce the chances of obtaining satisfactory data to achieve&#xD;
             the objectives of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women over 18 years old</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tamara Garrido, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>iPremom (Igenomix Preeclampsia SLU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Gomez, BSc, MSc</last_name>
    <phone>+34963905310</phone>
    <email>carlos.gomez@igenomix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Simon, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose AdÃ¡nez GarcÃ­a</last_name>
      <phone>+34 985 10 80 00</phone>
      <email>adamezjose@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de TorrejÃ³n</name>
      <address>
        <city>TorrejÃ³n De Ardoz</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MÂª Mar Gil Mira</last_name>
      <phone>+34 916 26 26 00</phone>
      <phone_ext>7197</phone_ext>
      <email>mmar1984@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Santa LucÃ­a</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Pedro MartÃ­nez CendÃ¡n</last_name>
      <phone>+34 968 12 86 00</phone>
      <phone_ext>953247</phone_ext>
      <email>jmartinezcen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Carlos Melchor Marcos</last_name>
      <phone>+34 944 00 60 55</phone>
      <email>jmelchorm@sego.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Amezcua Recover</last_name>
      <phone>+34 967 59 71 00</phone>
      <phone_ext>37505</phone_ext>
      <email>aamezcuar@aol.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular Materno Infantil</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Martin Martinez</last_name>
      <phone>+34 928 44 48 30</phone>
      <email>aliciammartinez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Palacios Marques</last_name>
      <phone>+34 965 93 34 60</phone>
      <email>ana.palacios.marques@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de CastellÃ³n</name>
      <address>
        <city>CastellÃ³n De La Plana</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Lozano Moreno</last_name>
      <phone>+34 964 72 51 64</phone>
      <email>ginelozano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina SofÃ­a</name>
      <address>
        <city>CÃ³rdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MÂª Inmaculada Romero Nieto</last_name>
      <phone>+34 957 01 03 52</phone>
      <email>minmaromero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar MartÃ­nez PÃ©rez</last_name>
      <phone>+34 911 91 64 23</phone>
      <email>oscarmartinezgine@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Luis Delgado</last_name>
      <phone>+34 968 36 96 74</phone>
      <email>juanluisdelgado@tokos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Regional de MÃ¡laga</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JesÃºs JimÃ©nez LÃ³pez</last_name>
      <phone>+34 951 29 22 06</phone>
      <email>jesuss.jimenez.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nieves GonzÃ¡lez GonzÃ¡lez</last_name>
      <phone>+34 922 67 85 76</phone>
      <email>nlglez@ull.edu.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del RocÃ­o</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucas Cerrillos GonzÃ¡lez</last_name>
      <phone>+34 955 01 27 01</phone>
      <email>lcerrillog@sego.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y PolitÃ©cnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Perales Marin</last_name>
      <phone>+34 961 24 40 00</phone>
      <email>perales_alf@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del RÃ­o Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Maria Arias Valdes</last_name>
      <phone>+34 983 42 04 00</phone>
      <phone_ext>85730</phone_ext>
      <email>eariasva@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel OrÃ³s LÃ³pez</last_name>
      <phone>+34 976 76 88 78</phone>
      <email>danoros@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Campillos Maza</last_name>
      <phone>+34 976 76 55 00</phone>
      <phone_ext>143223</phone_ext>
      <email>jmcampillos@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Early onset Preeclampsia (EOPE)</keyword>
  <keyword>Late onset Peeclampsia (LOPE)</keyword>
  <keyword>First trimester</keyword>
  <keyword>Early screening</keyword>
  <keyword>Circulating RNA (C-RNA)</keyword>
  <keyword>Molecular profile</keyword>
  <keyword>Blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

